D.O | Jotup

BrainCheck Showcases Latest Innovations at American Medical Group Association Annual Conference

Retrieved on:

Tuesday, April 9, 2024

Diagnosis, AMGA, Conference, Screen, Deficit spending, Risk, Patient, Tablet, American Medical Group Association, MD, D.O, Summit Health, Amnesia, Cognition, Pathology, Dementia, FDA, Medical device

AUSTIN, Texas, April 9, 2024 /PRNewswire/ -- BrainCheck, Inc., a digital health innovator delivering next-generation technology into the growing digital cognitive assessment market, will showcase its comprehensive cognitive assessment platform, including its latest innovation, Screen™, in booth #202 at the American Medical Group Association (AMGA) Annual Conference from April 9-12 in Orlando, FL. Chelsea Dugan, Vice President of Marketing, and members of the BrainCheck team will attend the event to share BrainCheck's latest technology with medical groups and health system executives nationwide.

Key Points:

Chelsea Dugan, Vice President of Marketing, and members of the BrainCheck team will attend the event to share BrainCheck's latest technology with medical groups and health system executives nationwide.
Expertly designed with patients in mind, BrainCheck's clinically proven platform offers a comprehensive digital solution, streamlining screening, assessment, care planning, and monitoring.
"BrainCheck's technology has transformed the way we assess patients' cognitive health in our practice," said Eric R. Penniman, D.O., Executive Medical Director, Summit Medical Group.
Early detection of cognitive impairment is key to unlocking opportunities to preserve patients' brain health," said Reza Ghomi, MD, MSE, neuropsychiatrist and Chief Medical Officer at BrainCheck.

Bio-Path Holdings Reports Full Year 2023 Financial Results

Retrieved on:

Friday, March 8, 2024

Division, Research, AML, University, Clinical trial, Chronic lymphocytic leukemia, CLL, Holding, MD Anderson Cancer Center, Patient, D.O, Lymphoma, KOL, Pharmaceutical industry

“2023 was a year of focused execution, as evidenced by the continued progress across our pipeline of DNAbilize programs,” said Peter Nielsen, President and Chief Executive Officer of Bio-Path Holdings.

Key Points:

“2023 was a year of focused execution, as evidenced by the continued progress across our pipeline of DNAbilize programs,” said Peter Nielsen, President and Chief Executive Officer of Bio-Path Holdings.
As of December 31, 2023, the Company had cash of $1.1 million, compared to $10.4 million as of December 31, 2022.
Net cash provided by financing activities for the year ended December 31, 2023 was $2.2 million.
ET to review these full-year 2023 financial results and to provide a general update on the Company.

embecta-sponsored Educational Symposium and Abstracts at ATTD Highlight Role of Insulin Pumps in the Management of Type 2 Diabetes

Retrieved on:

Wednesday, March 6, 2024

Additionally, six embecta-sponsored abstracts focusing on injection and insulin pump therapies have been selected for presentation as scientific posters at ATTD 2024.

Key Points:

Additionally, six embecta-sponsored abstracts focusing on injection and insulin pump therapies have been selected for presentation as scientific posters at ATTD 2024.
Entitled “Unlocking the potential of insulin pumps for personalized T2D care,” the symposium aims to highlight the significance of insulin pump therapy among the extensive treatment options available for type 2 diabetes (T2D).
The six embecta-sponsored abstracts set for presentation as scientific posters, include robust data about insulin therapy via both pumps and multiple daily injections (MDI).
Another poster highlights data showing that in individuals with type 2 diabetes, insulin pump therapy eases constraints imposed by diabetes management and improves quality of life.

BON SECOURS MERCY HEALTH AND COMPASS SURGICAL PARTNERS TO OPEN STATE-OF-THE-ART OUTPATIENT SURGERY CENTER IN SPRINGFIELD, OHIO

Retrieved on:

Wednesday, February 7, 2024

SPRINGFIELD, Ohio and RALEIGH, N.C., Feb. 7, 2024 /PRNewswire/ -- Springfield Regional Outpatient Surgery Center, a joint venture between Bon Secours Mercy Health, Compass Surgical Partners (Compass), and local physicians, today announced the opening of its new 12,000-square-foot ambulatory surgery center (ASC) in Springfield, Ohio.

Key Points:

SPRINGFIELD, Ohio and RALEIGH, N.C., Feb. 7, 2024 /PRNewswire/ -- Springfield Regional Outpatient Surgery Center, a joint venture between Bon Secours Mercy Health, Compass Surgical Partners (Compass), and local physicians, today announced the opening of its new 12,000-square-foot ambulatory surgery center (ASC) in Springfield, Ohio.
Located at 2610 North Limestone Street, Springfield Regional Outpatient Surgery Center will offer procedures across a host of specialties, including neurosurgery, orthopedics, podiatry, plastic surgery, interventional pain management, OB/GYN, gastroenterology and general surgery.
"Compass is thrilled to partner with Mercy Health to establish and operate the Springfield Regional Outpatient Surgery Center, which will provide top-notch care in a comfortable outpatient setting," added Scott Bergman, Market President at Compass Surgical Partners.
Springfield Regional Outpatient Surgery Center is seeking accreditation from the Accreditation Association for Ambulatory Health Care and certification from Medicare.

EKU Launches Feasibility Study for a College of Osteopathic Medicine

Retrieved on:

Tuesday, January 23, 2024

Richmond, KY, Jan. 23, 2024 (GLOBE NEWSWIRE) -- Eastern Kentucky University (EKU) is seeking vendors to complete a feasibility study to analyze if a public College of Osteopathic Medicine is needed in the Commonwealth.

Key Points:

Richmond, KY, Jan. 23, 2024 (GLOBE NEWSWIRE) -- Eastern Kentucky University (EKU) is seeking vendors to complete a feasibility study to analyze if a public College of Osteopathic Medicine is needed in the Commonwealth.
The American Osteopathic Association describes the practice of osteopathic medicine as considering the whole person: mind, body and spirit.
The initiation of the feasibility study marks the first step in comprehending both the imperative need for the program and EKU's capacity to deliver an exceptional Doctor of Osteopathic Medicine (D.O.)
To initiate the feasibility study, EKU has issued a request for proposal (RFP), seeking to identify an agency that can complete the analysis and make a recommendation.

embecta Announces FDA 510(k) Submission for Insulin Patch Pump

Retrieved on:

Tuesday, January 9, 2024

Diabetes, Insulin, Food, EMBC, Type 2 diabetes, D.O, Caregiver, FDA, Growth, Medical device

PARSIPPANY, N.J., Jan. 09, 2024 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta") (Nasdaq: EMBC), a global diabetes care company with a 100-year legacy in insulin delivery, today announced that it has submitted a 510(k) premarket filing to the U.S. Food and Drug Administration (FDA) for a proprietary disposable insulin delivery system.

Key Points:

PARSIPPANY, N.J., Jan. 09, 2024 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta") (Nasdaq: EMBC), a global diabetes care company with a 100-year legacy in insulin delivery, today announced that it has submitted a 510(k) premarket filing to the U.S. Food and Drug Administration (FDA) for a proprietary disposable insulin delivery system.
"This patch pump is intended for people who require insulin to manage diabetes and is informed by the unique needs of people with type 2 diabetes and their healthcare providers," said Colleen Riley, Chief Technology Officer, embecta.
"We worked with them to address the needs of those who may require more daily insulin and are looking for a simplified and convenient option for automated insulin delivery that offers the ease of use and discretion of a patch pump, along with a larger 300U insulin reservoir."
embecta continues to advance its patch pump development program, with plans for a closed-loop version including an insulin-dosing algorithm in a future FDA submission.

Bio-Path Holdings Successfully Completes First Dose Cohort of Phase 1/1b Clinical Trial of BP1002 in Refractory/Relapsed Acute Myeloid Leukemia

Retrieved on:

Thursday, December 14, 2023

RNA interference, Weill Cornell Medicine, Hospital, D.O, Hope, MD Anderson Cancer Center, Cornell University, Holding, University, Scripps Health, Toxicity, Acute myeloid leukemia, Patient, Safety, Clinical, Medicine, AML, Pharmaceutical industry

The first dose cohort consisted of a starting dose of 20 mg/m2, and there were no dose limiting toxicities.

Key Points:

The first dose cohort consisted of a starting dose of 20 mg/m2, and there were no dose limiting toxicities.
The approved treatment cycle is two doses per week over four weeks for a total of eight doses administered over twenty-eight days.
The Phase 1b portion of the study is expected to commence after completion of BP1002 monotherapy cohorts and will assess the safety and efficacy of BP1002 in combination with decitabine in refractory/relapsed AML patients.
Gail J. Roboz, M.D., is the National Principal Investigator for the Phase 1/1b trial.

Bio-Path Holdings Reports Third Quarter 2023 Financial Results

Retrieved on:

Wednesday, November 15, 2023

Acute myeloid leukemia, Clinical trial, Patient, Research, MD Anderson Cancer Center, D.O, Division, AML, Holding, Interim analysis, KOL, Pharmaceutical industry, Cryptocurrency, Decitabine

HOUSTON, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced its financial results for the third quarter ended September 30, 2023 and provided an update on recent corporate developments.

Key Points:

HOUSTON, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced its financial results for the third quarter ended September 30, 2023 and provided an update on recent corporate developments.
Announced Positive Results from Interim Analysis of Phase 2 Clinical Trial of Prexigebersen in Acute Myeloid Leukemia.
As of September 30, 2023, the Company had cash of $2.4 million, compared to $10.4 million as of December 31, 2022.
ET to review these third quarter 2023 financial results and to provide a general update on the Company.

ENT and Allergy Associates, LLP Continues to Add Talented Physicians Welcomes Otolaryngologist Monica Christine Azmy, M.D. to its Old Bridge, NJ Office

Retrieved on:

Monday, November 13, 2023

To achieve this objective, significant effort is made to seek out and attract top-tier talent trained at the nation’s leading institutions.

Key Points:

To achieve this objective, significant effort is made to seek out and attract top-tier talent trained at the nation’s leading institutions.
This continues with Monica Christine Azmy, M.D., who is the latest recruit to join the group's 240+ board-certified physicians.
Dr. Azmy will begin seeing patients at ENTA’s Old Bridge, NJ office effective October 1, 2024.
To learn more about ENTA, find a local office or book an appointment, visit www.entandallergy.com or call 1-855-ENTA-DOC.

UNIVERSITY OF NEW ENGLAND ONLINE OFFERING CONTINUING EDUCATION COURSES FOR THOSE LOOKING TO BOOST PROFESSIONAL SKILLS

Retrieved on:

Thursday, December 14, 2023

Online, Grief, Terminal illness, Learning, Social work, D.O, Spirituality, MSW, Humour, LMSW, University, Curriculum, End-of-life, UNE, Family, Palliative care, Empathy, Education, Nursing

PORTLAND, Maine, Dec. 14, 2023 /PRNewswire/ -- The University of New England (UNE) Online has long been recognized as a leader in providing high-quality, 100% online graduate degree programs in numerous disciplines. Now, they are expanding their offerings to include continuing education programs across a wide array of fields.

Key Points:

Now, they are expanding their offerings to include continuing education programs across a wide array of fields.
Beth Taylor-Nolan, dean of UNE Online, said, "Our continuing education programs and courses are designed to help individuals acquire professional expertise, stay current with industry trends, and expand their career prospects.
The University of New England Online (UNE Online) offers a diverse range of continuing education programs, courses and professional certificates designed to enhance skills, broaden knowledge, and promote lifelong learning.
UNE Online's continuing education programs cater to a variety of interests and fields, ranging from healthcare and business to social work and education.